|
|||||
|
|
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study |
|
| Authors: | Su Jinmei Li Mengtao He Lan Zhao Dongbao Wan Weiguo Liu Yi Xu Jianhua Xu Jian Liu Huaxiang Jiang Lindi Wu Huaxiang Zuo Xiaoxia Huang Cibo Liu Xiumei Li Fen Zhang Zhiyi Liu Xiangyuan Dong Lingli Li Tianwang Chen Haiying Li Jingyang He Dongyi Lu Xin Huang Anbin Tao Yi Wang Yanyan Zhang Zhuoli Wei Wei Li Xiaofeng Zeng Xiaofeng |
| Institution: | 1.Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Immunologic Diseases, Ministry of Science and Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China ;2.Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China ;3.Department of Rheumatology, Changhai Hospital, Shanghai, China ;4.Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China ;5.Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China ;6.Department of Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China ;7.Department of Rheumatology, The First Affiliated Hospital of Kunming Medical University, Kunming, China ;8.Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, China ;9.Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China ;10.Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China ;11.Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China ;12.Department of Rheumatology, Beijing Hospital, Beijing, China ;13.Department of Rheumatology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China ;14.Department of Rheumatology, The Second Xiangya Hospital of Central South University, Changsha, China ;15.Department of Rheumatology, The First Affiliated Hospital of Harbin Medical University, Harbin, China ;16.Department of Rheumatology, Peking University Third Hospital, Beijing, China ;17.Department of Rheumatology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China ;18.Department of Rheumatology, Guangdong Second Provincial General Hospital, Guangzhou, China ;19.Department of Rheumatology, The Third Hospital of Hebei Medical University, Shijiazhuang, China ;20.Department of Rheumatology, Zhuzhou Central Hospital, Zhuzhou, China ;21.Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China ;22.Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China ;23.Department of Rheumatology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China ;24.Department of Rheumatology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China ;25.Department of Rheumatology, Jiangsu Province Hospital, Nanjing, China ;26.Department of Rheumatology, Peking University First Hospital, Beijing, China ;27.Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China ;28.Department of Rheumatology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China ; |
| Abstract: | Clinical Rheumatology - The equivalence of the biosimilar HS016 to adalimumab (Humira) for the treatment of active ankylosing spondylitis (AS) patients has been previously validated. The aim was to... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |